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Background. Recently, antimicrobial peptides (AMPs) have been investigated for their use in cancer therapy. )ey have been
reported to selectively target and kill cancer cells whilst leaving normal healthy cells unaffected. Certain Anura AMPs have
expressed selective cytotoxicity against tumour cells. Aim. To test the potential of Anura AMPs bombinin H2, bombinin H4,
temporin A, and temporin L for use as therapeutic agents for non-small cell lung carcinoma (NSCLC).Methods. Cytotoxic effects
on NSCLC cell lines A549 and Calu-3 and normal epithelial cell line Beas-2B were tested using the CellTox Green Cytotoxicity
Assay.)eir haemolytic effects on human erythrocytes were also tested for their clinical relevance. Cell membrane profiling, using
MALDI-TOF, was performed to ascertain if membrane characteristics of the NSCLC and Beas-2B cell lines may contribute to the
AMPs mode of action. Results. Bombinin H4 (100–1.5 μM, p< 0.05) and temporin A (100–50 μM, p< 0.05) showed selective
cytotoxicity towards the NSCLC cell lines. Furthermore, they exhibited low levels of haemolytic activity (bombinin H4, 0.061%;
temporin A, 0.874%) comparable to untreated cells. Cell membrane profiling showed the phospholipid composition of normal
epithelial cell line Beas-2B to be divergent from the cancerous cell lines. However, there was an overlap in the phospholipid profiles
of the NSCLC cell lines supporting the hypothesis that the AMPs may have a selective affinity via the membrane composition of
cancerous cell lines. Conclusion. )ese results suggest that bombinin H4 and temporin A show potential for application in lung
cancer therapies. Further in vitro and in vivo studies are required to develop a greater understanding of their use as
anticancer agents.
1. Introduction
In 2018, it was reported that there were an estimated 17
million new cancer cases and 9.6 million cancer related
deaths worldwide, with lung cancer being the most
common cause of death [1]. Lung cancer is commonly
treated via chemotherapy [2]. However, the success of this
treatment is limited due to the rise of chemotherapeutic
resistance in cancer cells due to alterations occurring
within membrane transporter proteins such as multidrug
resistance (MDR) proteins and P-glycoprotein. Further-
more, the nonspecific targeting of the chemotherapy
agents results in their toxicity towards healthy dividing
cells, causing deleterious side effects such as nausea,
diarrhoea, hair loss, anaemia, and infections, all of which
reduce the patients’ overall quality of life. Unfortunately,
the prognosis of lung cancer patients has not shown the
same level of improvement over recent years as has been
observed in other cancers such as breast and prostate [3].
Following an average of 4–6 months’ posttreatment ini-
tiation, patients suffer disease progression, highlighting
the long term ineffectiveness of the current treatments and
aggressiveness of the disease [4]. )e 5-year survival rate
for non-small cell lung cancer (NSCLC) is currently only
10–20% [5]. It is therefore imperative that new drug
treatments that have neither the toxicity nor the mecha-
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Antimicrobial peptides (AMPs) are a group of com-
pounds that are a conserved element of the innate im-
mune response [6], found in all species investigated such
as bacteria, fungi, plants, insects, birds, fish, amphibians,
and mammals [6, 7]; these small peptides are between 12
and 50 amino acids long [8]. )ey have been shown to
effectively kill a wide range of micro-organisms such as
viruses, fungi, and both Gram-positive and -negative
bacteria [9]. AMPs are grouped into two sets: those which
are toxic to bacteria and cancer cells but not to non-
cancerous mammalian cells and those which are toxic
towards all three cell types [10]. AMPs specific selectivity
for cancer cells over normal epithelial cells is generally
attributed to several complimenting characteristics be-
tween the cancer cell membranes and the AMPs. Such
characteristics include their ability to interact electro-
statically with each other, hydrophobicity of the AMPs
represented as therapeutic index, and the sequence of the
AMP. )e electrostatic interaction between the AMP and
the target cell membrane is one of the key drivers of
interaction, with AMPs typically being cationic with a net
positive charge between +2 and +7 due to an excess of
basic amino acids such as arginine, lysine, and histidine
[11]. Not all AMPs possess anticancer properties but those
that do, anticancer peptides (ACPs), have been recognised
as being more specific in their effects, producing less
harmful side effects than chemotherapy and traditional
therapies [10, 12, 13].
AMPs found in Anura frog skin secretions have been
used medicinally for many years. )e dorsal skin secre-
tions collected from Anura are amongst the richest sources
of naturally formed AMPs, acting as part of the defence
mechanisms to protect the frog skin from pathogen in-
vasion and predator ingestion [14]. )e Anura expels the
AMPs, along with other molecules such as alkaloids,
neuropeptides, and biogenic amines, in large amounts in
response to threat or injury [15]. Each Anura species se-
cretes a unique set of AMPs which leads to the variety in
properties such as antimicrobial, anticancer, and hae-
molytic effects [16]. Certain Anura AMPs have been ob-
served to express selective cytotoxicity against tumour
cells, such as AMPs from African claw frogs from the
Pipidae family which have demonstrated tumouricidal
properties against small cell lung cancer cell lines [17] and
bladder cancer cell lines [18] as well as a range of he-
matopoietic cell lines [19].
)e purpose of this study is to investigate antimicrobial
peptides from the Anura species Rana temporaria (tem-
porin A and temporin L) [20] and Bombina variegata
(bombinin H2 and bombinin H4) [21] to determine
whether they display selective cytotoxicity towards lung
cancer cells, thus offering potential as new chemothera-
peutic agents to treat lung cancer. )e percentage of cell
viability with AMPs at varying concentrations and time
points was tested using lung cancer cell lines (A549 and
Calu-3) as well as noncancer cell line (Beas-2B). Fur-
thermore, cell membrane characterisation was analysed to
determine if membrane composition may affect the AMPs
mode of action.
2. Materials and Methods
2.1. Peptides. Temporin A [FLPLIGRVLSGIL], temporin L
[FVQWFSKFLGRIL], bombinin H2 [IIGPVLGLVG-
SALGGLLKKI], and bombinin H4 [I–(D-allo-1)
GPVLGLVGSALGGLLKKI] were synthesized by Selleck
Chemicals (Houston, TX, USA).
2.2. Peptide Validation. Matrix assisted laser desorption/
ionisation (MALDI) mass spectrometry analysis was carried
out on the samples following the addition of 100 μl of 0.1%
formic acid to solubilise the peptide.)ematrix solution was
made up of α-cyano-4-hydroxycinnamic acid (10mg/ml)
combined with a 50 : 50 solution acetonitrile and 0.1% tri-
fluoroacetic acid. When all the samples were dry, the
MALDI plate was loaded into the Voyager-DE STR Bio-
spectrometry Workstation (Applied Biosystems, Framing-
ham, MA). Data acquisition parameters were set: ion mode,
positive; instrument mode, reflector; instrument range, 1000
to 4000Da; lowmass gate, 1000Da; total scans, 100 shots per
spectrum; accelerating voltage, 20,000V. )e results were
analysed using Voltage Data ExplorerTM version 4.0 (Ap-
plied Biosystems, Framingham, MA). )e spectrum was
calibrated against the reference proteins (angiotensin, bra-
dykinin, and neurotensin).
Electrospray ionisation (ESI) mass spectroscopy was
used in combination with MALDI mass spectroscopy to
further validate the peptide identities. Each peptide was
mixed with 100 μl of methanol before being pipetted into the
LTQOrbitrap XL ()ermo Fisher Scientific, Waltham,MA).
)e peptides were fragmented in higher-energy collisional
dissociation (HCD) mode with an isotope band width of
1.5m/z.
2.3. Antimicrobial Properties. Staphylococcus epidermidis
1457 and S. epidermidis 5179-R1 were cultured on horse
blood agar plates for 24 hours at 37°C and subsequently used
to inoculate 3ml of prewarmed Tryptic Soy Broth (TSB;
Becton Dickinson, Cockeysville, USA). Precultures were
grown in a shaking incubator for 2–3 hours at 37°C and used
to inoculate 200 μl fresh TSB in 96-well tissue culture plates
(NUNC, )ermo Fisher Scientific, Roskilde, Denmark) to a
starting OD600 of 0.05. To each test well, 100 μM of peptides
was added. )is concentration was chosen as it was the
upper limit of the concentrations being investigated for
anticancer potential. Untreated bacteria were used as
controls.
)e 96-well plate was inserted into a BMG FLUOstar
Omega microplate reader (BMG LABTECH, Germany) set
to a wavelength of 600 nm. )e OD of each well was read
every hour over 24-hour period, to determine the effect of
the AMPs on the growth rate/population density of the
bacteria. All experiments were performed in triplicate, and
each strain and condition tested in triplicate.
2.4. Cell Culture. NSCLC cell line A549 (ATCC–CCL185)
and normal epithelial cell line Beas-2B (ATCC CRL-9609)
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were routinely grown in DMEM (Corning, )ermo Fisher
Scientific, Basingstoke, UK) supplemented with 10% foetal
bovine serum (FBS) (South American Origin, Biosera,
Uckfield, UK), 2mM L-glutamine (Gibco, )ermo Fisher
Scientific, Basingstoke, UK), and 1% penicillin/streptomycin
(Gibco, )ermo Fisher scientific, Basingstoke, UK). )e
NSCLC cell line Calu-3 (ATCC HTB55) was routinely
grown in RPMI-1640 (Corning, )ermo Fisher Scientific,
Basingstoke, UK) supplemented with 10% FBS, 2mM
L-glutamine, and 1% penicillin/streptomycin. All cells were
incubated at 37oC and 5% CO2.
2.5. Cytotoxicity Assays
2.5.1. CellTox Green Cytotoxicity Assay. )e CellTox Green
Cytotoxicity Assay was used to determine reduction in
membrane integrity due to AMP treatment. CellTox Green
Dye was mixed with cell stock made in phenol-free, serum-
free medium to a ratio of 1 μl dye: 1000 μl cell stock. Phenol-
free medium decreases the background noise of the fluo-
rescence reading so that a more accurate reading can be
taken. )is solution was then used to dilute the peptide to
specific concentrations (100 μM, 50 μM, 25 μM, 12.5 μM,
6.25 μM, 3 μM, 1.5 μM). Once the cells were dosed, the plates
were maintained at a temperature of 37°C and 5% CO2.
Untreated cells, comprising media and CellTox Green Dye,
were used as a control; cell lysis buffer (provided in the
CellTox Cytotoxicity Assay kit) was used as a positive
control, indicating cell death.
Fluorescence readings were taken using a POLARstar
Omega plate reader (BMG LABTECH, Germany) at 24
hours in accordance with published literature [22, 23]. )e
plate was read from the bottom optic at 485–510 nm exci-
tation and 520–530 nm emission, with gain adjusted to 1500
OD.)e gain was optimised so that the maximum value was
not reached by any of the peptides for any cell lines over the
24 h treatment. Readings were corrected against the blank
average. Only the peptides which were cytotoxic to the
NSCLC cell lines, A549 and Calu-3, were tested for selec-
tivity on the normal lung epithelial cell line, Beas-2B. All
experiments were performed in triplicate.
2.5.2. Haemolytic Assay. )e HaemoScan Biomaterial
Haemolytic Assay (HaemoScan, Netherlands) was used to
investigate the cytotoxicity of the AMPs on human eryth-
rocytes. Only the AMPs which displayed selective cyto-
toxicity towards the cell lines A549 and Calu-3 were tested
for haemolytic properties.
)e protocol of the assay was followed according to the
manufacturers’ instructions. In summary, the erythrocyte
suspension was prepared by adding 5ml of the supplied
wash buffer to the erythrocyte suspension and centrifuging
at 400× g for 10 minutes. )e supernatant was then re-
moved. )is step was repeated twice with the wash buffer,
and the steps were then repeated replacing wash buffer with
dilution buffer twice more. )e final pellet was then sus-
pended in 5ml of dilution buffer to form a colourless
supernatant.
)e minimum concentration of each peptide that had a
significant effect on A549 and/or Calu-3 without signifi-
cantly effecting noncancer cells (Beas-2B) was added to
0.5ml of erythrocyte suspension (bombinin H4, 6.25 μM;
temporin A, 50 μM). A haemoglobin calibration curve was
also produced to establish the haemoglobin concentrations
present in the treatment groups of the erythrocyte sus-
pension after exposure to the AMPs.
Both the calibrator and treatment groups were then
incubated at 37°C for 24 hours. After 24 hours of incubation
the samples were centrifuged at 4000× g for 1 minute and
20 μl of the supernatant pipetted into a 96-well plate along
with 180 μl of assay buffer. )e plate was agitated on a plate
shaker before being read on a BMG FLUOstar Omega
microplate reader (BMG LABTECH, Germany). )e ab-
sorbance was read at three wavelengths, 380, 415, and
450 nm (Harboe method), and the calculation
(2× 415)–(450 + 380) was applied to give a final OD.
Haemoglobin concentrations of the test samples were
then established by comparing the treatment readings
against the haemoglobin calibration curve.)e haemoglobin
concentration of the treatment groups was presented as a
percentage of the total haemoglobin present in the sample,
expressed as percentage haemolysis. All experiments were
performed in triplicate.
2.6. Cell Membrane Characterisation
2.6.1. Phospholipid Extraction and MALDI-TOF MS
Analysis. Prior to phospholipid analysis, cultured cell lines
were harvested as follows: culture medium was discarded
from the flasks; the cells were washed with 10ml PBS and
were subsequently incubated with 3ml 0.025% trypsin/
EDTA for 3–5min. )e reaction was terminated by the
addition of 10ml cell culture medium, and the samples were
centrifuged at 10,000× g for 5min.
Cell pellets were then solubilised in 200 ul of chloro-
form: methanol (2 : 1) and then diluted (1 : 5) in either
dihydroxybenzoic acid (DHB) at a concentration of 10mg/
ml in methanol containing 0.1% trifluoroacetic acid or
para-nitroaniline (PNA) at a concentration of 10mg/ml in
chloroform: methanol (2 : 1). One microliter of each
mixture was then spotted on a clean MALDI plate (Applied
Biosystems). Samples were analysed using a Voyager-DE
STR, MALDI-TOF mass spectrometer (Applied Bio-
systems, Framingham, MA). A 337 nm specific laser
wavelength was used to ensure that only the outer mem-
brane was detected. Data acquisition parameters were set:
time delay of 200 nanoseconds, total scans of 100 shots per
spectrum, and accelerating voltage of 20,000 V. )e two
matrices (DHB and PNA) were utilised and run in both the
positive and negative modes, respectively. )e m/z signal
was aligned across each sample within 0.5 of each other
using Excel. )e results were analysed and normalised
using Voltage Data ExplorerTM version 4.0 (Applied Bio-
systems, Framingham, MA). Any background noise was
removed, m/z values between 1 and 1600 were collected,
and new spectra were established.
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2.6.2. Identification and Charge of Phospholipids. Possible
identities of each membrane component at specific m/z
values were assigned according to the work of Estrada and
Yappert [24], e.g., PC (40 : 6), which represents the head-
group (number of carbons in the fatty acid chain: number of
double bonds).
2.7. Statistical Analysis. Intragroup data readings were
checked for outliers using the Grubbs test, identifying
outliers with a p value greater than 0.05 when compared
with the expected distribution of results. Any outliers
identified were excluded from further statistical analysis. A
one-sample Kolmogorov–Smirnov (K–S) test was carried
out on each data group to test the normality of the data to
determine appropriate further data analysis tests. All data
was shown to be of a non-normal distribution and therefore
a Kruskal–Wallis nonparametric analysis was carried out. To
identify any significant differences between groups, a
Mann–Whitney test was used to test individual treatment
groups against the untreated control group. A p value of
<0.05 was considered significant.
3. Results
MALDI and ESI mass spectrometry confirmed that the
synthetically made identities of each peptide accurately
represented the peptide found from the natural source,
Anura bombinin H2 and its diastereomer bombinin H4,
containing a D-alloisoleucine at the second N-terminal
residue as a result of a posttranslational modification,
temporin A, and temporin L [25].
3.1. Antimicrobial Properties. Untreated S. epidermidis 1457
and 5179-R1 underwent rapid proliferation throughout the
initial 8 hours, reaching a maximum OD600 of 0.95 and 0.7,
respectively, after 10 hours before entering a stationary phase.
For S. epidermidis 1457, bombinin H2, bombinin H4, and
temporin L (100 μM) significantly inhibited proliferation over
the 24 hours (p≤ 0.001; Figure 1), whilst only bombinin H2
and bombinin H4 (100 μM) significantly inhibited growth of
S. epidermidis 5179-R1 (p≤ 0.001; Figure 1(b)).
3.2.CellCytotoxicity. When bombinin H2 was applied to the
A549 cell line, statistical analysis showed significant cell
death between the untreated cells and the treated cells at
concentrations ranging from 12.5 μM to 50 μM (p≤ 0.05).
For Calu-3 cells, bombinin H2 resulted in significant cell
death, when compared to the control, at concentrations of
50 μM and 100 μM (p≤ 0.001) (Figure 2(a)). However,
significant cell death also occurred when the noncancerous
cell line Beas-2B was treated with bombinin H2 at con-
centrations of 12.5 μM to 100 μM. )ese data show that
bombinin H2 is not selectively cytotoxic to cancer cells.
Bombinin H4 proved to be highly toxic to the A549 cell
line after 24-hour exposure, with significant cell death being
observed from 1.5 μM to 100 μM (p≤ 0.05). However, in the
Calu-3 cell line, significant cell death was only observed in
the higher concentrations, 50 μM and 100 μM (p≤ 0.001),
when compared to the untreated cells (Figure 2(b)). In the
Beas-2B cell line, significant cell death was observed at
12.5 μM–100 μM (p≤ 0.05). As bombinin H4 showed se-
lective cytotoxicity to A549 cells at the lowest concentration
tested but not in the Beas-2B cells, it is suggested that
bombinin H4 exhibits some level of selective cytotoxicity.
Interestingly, temporin A showed a dual effect on the
A549 cell line. At concentrations of 50 μM and 100 μM
(p≤ 0.001), significant cell death was observed. However, at
concentrations of 3 μM–25 μM, a significant increase in cell
viability was observed (p≤ 0.050). For Calu-3 cells, 50 μM
and 100 μM temporin A induced significant cell death
(p≤ 0.01) when compared to the untreated cells but, unlike
A549, did not increase cell viability at the lower concen-
trations (Figure 2(c)). When temporin A was applied to the
Beas-2B cell lines, significant cell death was only observed at
100 μM (p≤ 0.05). From these results, it could be suggested
that temporin A is selectively cytotoxic at 50 μM.
)e A549 cell line treated with temporin L at concen-
trations of 1.5 μM–25 μM (p≤ 0.05) resulted in significant
cell death when compared to the untreated cells. In the Calu-
3 cell line, temporin L induced significant cell death across
the whole range of concentrations, 1.5 μM–100 μM
(p≤ 0.05), when compared to the untreated cells
(Figure 2(d)). As with Calu-3 cell line, Beas-2B cell line
showed significant cell death across the whole temporin L
concentration range, 1.5 μM–100 μM (p≤ 0.05), when
compared to the untreated cells. Temporin L, therefore, was
shown not to be selectively cytotoxic.
3.3. Haemolytic Properties. In the previous cytotoxicity in-
vestigations, only bombinin H4 and temporin A were
identified to have selective cytotoxicity potential towards lung
cancer cells, A549, and/or Calu-3 cell types, over noncan-
cerous cell line Beas-2B. )erefore, due to their selective
cytotoxic characteristics, only bombinin H4 and temporin A
were investigated for haemolytic activity after 24 h treatment
at 6.25 μM and 50 μM, respectively. Interestingly, whilst
bombinin H4 did not produce a cytotoxic effect on eryth-
rocytes, levels of haemolysis were significantly less than
untreated cells (p≤ 0.001), suggesting that bombinin H4 may
have a protective effect on erythrocytes viability. Temporin A,
though nontoxic to erythrocytes with a haemolysis value
comparable to untreated cells (p≤ 1.000), did not display the
same protective attributes as bombinin H4 (Table 1).
3.4. Cell Membrane Characterisation. )e phospholipid
profile of each cell line membrane was studied in order to
understand the possible differences it presents to an AMP
and hence the potential impact of membrane structure on
AMP cytotoxic activity. Principle component analysis (PCA)
using positive ionisation MALDI-TOF (Figure 3(a)) showed
that Beas-2B, A549, and Calu-3 cell lines were distinct from
one another whilst staying clustered within their cell type,
indicating that membrane phospholipid expression was
different among all three cell lines. Negative-mode MALDI-
TOF principle component analysis showed the phospholipid
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composition of normal epithelial cell line Beas-2B to be
divergent from the cancerous cell lines. However, we found
that there was an overlap of the phospholipid profiles of the
A549 and Calu-3 cancer cell lines (Figure 3(b)) which may
help explain why the AMPs had a similar effect upon the
cancerous cell lines but reacted differently with the non-
cancerous Beas-2B.
Membrane phospholipid expression profiles were also
compared to try and identify any differences in cell mem-
brane composition, which may account for the different
effect the AMPs had on cell toxicity. When comparing the
normal epithelial cell line Beas-2B with the NSCLC cell line
A549, twenty-four significant peaks were acquired where the
phospholipid was more abundant in either Beas-2B or A549
(p< 0.05); thirteen of the twenty-four had a p value of
<0.005 (Figure 3(b)). When comparing Beas-2B cell line
with NSCLC cell line Calu-3, thirty-two membrane com-
ponents were found to be significantly different (p< 0.05)
with twenty of those having a p value of 0.005.
)e variation in abundance of the phospholipids be-
tween cell lines (Figure 4) represents how the presence af-
fects the overall cell membrane charge. )e average relative
intensities (%) of the identified lipid species were allocated
their corresponding charge, the abundance of which was
used to create a percentage of negative and positive phos-
pholipids within each cell line. Beas-2B cells had a greater
percentage of positive phospholipids and fewer negative
phospholipids in comparison to A549 and Calu-3 cell lines
(p< 0.05). When Calu-3 and A549 cells were compared,
Calu-3, the stage III cancer cell line, was found to be more
negatively charged (1.7%) than the A549 cell line.
4. Discussion
Cancer treatments can vary: surgery, chemotherapy, ra-
diotherapy, or a combination of these treatments. With
specific regard to lung cancer, 90% of individuals with small
cell lung cancers will initially respond to chemotherapeutic
treatment, but almost all will relapse with multidrug re-
sistant disease, whilst patients with non-small cell lung
cancer have a low response rate to chemotherapy due to
inherent drug resistance [26]. In recent years, AMPs have
attracted attention as potential anticancer drugs due to
reports that they can selectively target and kill cancer cells
whilst leaving normal healthy cells unaffected, thus making
them attractive candidates for investigation. AMPs found in
Anura have been used for medicinal purposes for years, yet
only a handful of studies have reported the cytotoxic effects
of Anura AMPs against different cancer types [17, 18];
therefore, we sought to determine if the AMPs bombinin H2,
H4 (from the Anura species Bombina variegate) and tem-
porin A and L (from the Anura species Rana temporaria)
displayed selective anticancer activity, thus offering potential
as new chemotherapeutic agents to treat lung cancer.
In this study we have been able to demonstrate that
temporin A and bombinin H4 interacted more effectively
towards the NSCLC cell lines than in the normal lung cell
line. Temporin A showed the greatest potential as an anti-
cancer agent due to its ability to initiate significant cell death
in both NSCLC cell lines, at the same concentration, without
significant cell death in the Beas-2B cell line. Interestingly,
bombinin H4 selectively killed A549 cells but not Calu-3
cells. )e difference in the ability of bombinin H4 to induce
cytotoxic activity in the cancer cell lines suggests a difference
in the cell membrane protein composition of the two cancer
cell lines as a possible explanation for this observed effect.
)e membrane phospholipid profile demonstrated that the
cell lines clustered into distinct groups, suggesting that the
cells could have a distinct phospholipid compositional
signature on their outer leaflets. However, upon investiga-
tion of the outer membranes in negative-mode MALDI-
TOF, PCA showed that whilst Beas-2B cells have a distinct
phospholipid signature from that of the cancerous cells, the
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Figure 1: (a) Effects of the AMPs on Staphylococcus epidermidis 1457 over a 24-hour treatment period. (b) Effects of the AMPs on
Staphylococcus epidermidis 5179-R1.
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lines have similar phospholipid profiles. )us, cell mem-
brane phospholipid composition, alone, cannot explain why
bombinin H4 was cytotoxic to A549 cells but not Calu-3.
)e charge of the cell membrane can also affect the
affinity of the AMP for selective targeting of cancerous cells.
As expected, we found that normal epithelial Beas-2B cells
had a greater percentage of positive phospholipids and fewer
negative phospholipids in comparison to the A549 and Calu-
3 cell lines. Although PCA could not identify specific dif-
ferences between the cell lines, normal mammalian cells
predominantly contain zwitterionic phospholipids within
their outer leaflet such as PC and SM, whilst negatively
charged phospholipids such as PS and PG reside on the inner
leaflet. In contrast, in cancer the negatively charged phos-
pholipids become externalised to the outer leaflet [27–30],
enhancing electrostatic interaction between the AMPs and
cancer cells.
When A549 and Calu-3 phospholipid chargers were
compared, we found Calu-3, the stage III cancer cell line, to
be more negatively charged (1.7%) than the A549 cell line.




























































































































































































































Figure 2:)e cytotoxic effects observed on A549, Calu-3, and Beas-2B cell lines induced by (a) bombinin H2, IC50 value: 5.632×10−7 (95%
CI 3.935×10−7 to 7.9×10−7); (b) bombinin H4, IC50 value: 5.637×10−7 (95% CI 3.935×10−7 to 7.9×10−7); (c) temporin A, IC50 value:
5.637×10−7 (95% CI 3.935×10−7 to 7.9×10−7); and (d) temporin L, IC50 value: 5.632×10−7 (95% CI 3.935×10−7 to 7.9×10−7).
Table 1: )e mean percentage haemolysis induced by AMPS
bombinin H4 and temporin A.






electrostatic interaction, it is surprising that the more
negatively charged Calu-3 cells were not as susceptible to
bombinin H4 as the A549 cells.
)us, another factor that needs to be taken into con-
sideration is the properties of the AMPs themselves. Tem-
porin A was cytotoxic to both cancer cell lines at the same
concentration, yet bombinin H4 induced cell death at much
lower concentrations in A549 than Calu-3. )us, it may be
argued that the peptide sequence of the AMP, itself, plays a
major role in its cytotoxic potential. Indeed, the sequence of
an AMP can affect its ability to interact with cell membranes.
Several early studies have demonstrated that peptide helicity is
important for toxicity [31, 32]. Incorporation of D-amino
acids into cell lytic peptides causes a reduction in their cy-
totoxicity on mammalian cells [33, 34]. Bombinin H4 has
single L-D-isomerization, which may be enough to reduce the
peptides alpha-helical content, in turn reducing its ability to
bind to cell membranes. )e disruption of the alpha-helical
content can lead to the disruption of the hydrophobic face of
the AMP with the positively charged residue on the cell
membrane [35]. )is in turn could prevent the binding of the
AMP to the membrane from weakened polar attraction. )is
structural change, in combination with a slightly lower
positive charge on the Calu-3 membrane, may help explain
why bombinin H4 was not as cytotoxic to this cell line.
Many studies investigating the anticancer properties of
AMPs use cell lines from different cancer types [12, 36, 37];
our study highlights the importance of investigating several
cancer cell lines, especially from the same cancer type, to
determine if any observed AMP anticancer effect is consis-
tently observed across multiple cell lines or is cell line specific.
For AMPs to be viable anticancer agents they must not
induce haemolytic responses in the patient. Temporin A and
bombinin H4 were tested on human erythrocytes to
investigate their haemolytic properties at the minimum
concentrations required to cause significant cell death in
NSCLC cell lines, A549 and Calu-3. Encouragingly, for
temporin A, we observed a haemolysis value comparable to
untreated cells. With bombinin H, haemolysis was signifi-
cantly less than the untreated control cells, suggesting that it
actually had a protective effective on erythrocyte viability.
)e membrane of erythrocytes is asymmetrically distributed
with glycolipids, phosphatidylcholine, and sphingomyelin
expressed on the outer membrane to form a hydrophilic
environment. )e surface charge of erythrocytes has been
shown to have a zeta potential of 10mV, which is considered
to be a neutral charge [38]. )us, the neutral charge of the
erythrocytes may not attract the predominantly positively
charged AMPs. Furthermore, the relative size of the cell lines
compared to the erythrocytes should also be considered.)e
cell lines assessed have a diameter of 90–240 μM, whereas the
erythrocytes have a diameter of 6-8 μM [39, 40].)erefore, it
could be suggested that the erythrocytes are too small to
attract the AMP, preventing haemolysis from occurring.
It is generally accepted that the selective cytotoxicity of
AMPs towards bacteria and cancer cells is due to both cell
types possessing a negative charge on their cell membranes.
)erefore, we sought to investigate if antimicrobial activity
could be used as an indicator of an AMPs anticancer po-
tential. Bombinins H2 and H4 showed significant antimi-
crobial activity towards S. epidermidis 1457 and 5179-R1 at
100 μM, whilst temporins A and L exhibited some antimi-
crobial effects on the bacteria but not to the same extent as
the bombinins. Given that bombinin H2 and temporin L
were not selectively cytotoxic and temporin A demonstrated
the most efficacious anticancer activity, the antimicrobial
effect of an AMP cannot be used as an indicator for its
anticancer potential.






















































Figure 3: (a) PCA scatterplot of normalisedMALDI-TOFDHB derived data. Phospholipid spread for six repeats of three in vitro cell lines is
shown (A549, Beas-2B, Calu-3). )e phospholipid profiles of each cell line appear to be clearly distinct from one another. (b) )e re-
lationship between six repeats for three in vitro cell lines via PCA is shown. )ere is an overlap in the phospholipid expression between he
cancerous cell lines, whereas the normal cell line was separate from the cancerous cells.
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5. Conclusion
Research on the anticancer properties of AMPs has in-
creased in recent years. Many of these studies use different
cancer cell lines but usually only one from a particular cancer
type. Here we show that the effectiveness of AMPs as an-
ticancer agents varies not just between AMPs but also be-
tween cancer types, even within a particular cancer type.
)erefore, it is imperative that studies are conducted using
more than one cell line from the same cancer type to as-
certain if an AMP cytotoxicity is cell line specific. Fur-
thermore, our preliminary investigation of four Anura
AMPs demonstrated that temporin A and bombinin H4may
hold potential as anticancer agents, and further in vitro and
in vivo work is now required to fully ascertain their anti-
cancer potential and mode of action.
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Figure 4: (a) )e relative intensity of the phospholipids showing differences between the cell lines, obtained via positive-mode MALDI-
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